Curcumin Supplementation Enhances Bone Marrow Mesenchymal Stem Cells to Promote the Anabolism of Articular Chondrocytes and Cartilage Repair

Rui Zhang¹, Qiaoxia Zhang², Zhiyu Zou¹,³, Zheng Li¹,⁴, Meng Jin¹,⁵, Jing An¹, Hui Li⁴, and Jianbing Ma⁴

Abstract
Mesenchymal stem cells derived from bone marrows (BMSCs) and curcumin derived from turmeric were used for osteoarthritis (OA) treatment, respectively. We invested the effects of curcumin supplementation for BMSC therapeutic effects. In vitro, rat BMSCs were identified by dual-immunofluorescent staining of CD44 and CD90, and flow cytometry. Primary articular chondrocytes were identified by toluidine blue staining and immunofluorescent staining of Col2a1. EdU incorporation, migration assay, real-time quantitative polymerase chain reaction, and Western blot analyses were performed to evaluate the alterations of chondrocytes cocultured with BMSCs. In vivo, the rat model of OA was established by monosodiumacetic acid. After intra-articular injection of allogeneic BMSCs, articular cartilage damage and OA progression were evaluated by histological staining, and Osteoarthritis Research Society International and Mankin score evaluation. Although curcumin alone did not improve cell viability of primary articular chondrocytes, it promoted proliferation and migration of chondrocytes when cocultured with BMSCs. Meanwhile, the expression of anabolic genes in chondrocytes was remarkably increased both at mRNA and protein levels. In OA rats, curcumin and BMSCs cooperated to greatly promote articular cartilage repair and retard OA progression. Therefore, curcumin supplementation enhanced the BMSC function for the proliferation and migration of articular chondrocytes, and anabolic gene expression of extracellular matrix in articular chondrocytes in vitro, and the generation of articular cartilage in vivo. Our study shed light on the potential clinical application of curcumin cooperated with BMSCs in cartilage repair for OA treatment.

Keywords
curcumin, BMSCs, OA, chondrocytes, cartilage

Introduction
Osteoarthritis (OA) is a common and unhealthy condition in older adults affecting populations of 250 million worldwide, causing serious economic burden on society and families.¹⁻³ This syndrome is becoming more prevalent as the obese population and number of joint injuries increase in the elderly.

¹ Translational Medicine Center, Honghui Hospital, Xi’an Jiaotong University, Xi’an, Shaanxi, China
² School of Basic Medicine, Xi’an Jiaotong University Health Science Center, Xi’an, Shaanxi, China
³ Department of Integrated Traditional Chinese Medicine & Western Medicine Orthopaedics, Honghui Hospital, Xi’an Jiaotong University, Xi’an, Shaanxi, China
⁴ Department of Joint Surgery, Honghui Hospital, Xi’an Jiaotong University, Xi’an, Shaanxi, China
⁵ School of Basic Medicine, Shanxi University of Traditional Chinese Medicine, Xi’an, Shaanxi, China

Submitted: October 22, 2020. Revised: January 13, 2021. Accepted: January 21, 2021.

Corresponding Authors:
Rui Zhang, Translational Medicine Center, Honghui Hospital, Xi’an Jiaotong University, Xi’an, Shaanxi 710054, China. Email: zhangruity12@163.com
Jianbing Ma, Department of Joint Surgery, Honghui Hospital, Xi’an Jiaotong University, Xi’an, Shaanxi, China. Email: 13299028888@163.com
The complicated pathogenesis of OA is mainly characterized by articular cartilage degeneration, synovial inflammation, subchondral bone deterioration, osteophyte formation, ligaments degeneration, and hypertrophy of the joint capsule. Articular cartilage degeneration and the synovitis are the main symptoms at early stages of OA. Chondrocytes are the unique cell type in articular cartilage tissue implicated in the synthesis and maintenance of the extracellular matrix (ECM), which is responsible for the supply of chondrocyte nutrients and the disposal of metabolic waste, mainly containing type II collagen (Col2) and Aggrecan. The decrease of chondrocyte in elderly people causes the alteration in ECM composition and is contributing to the impaired capability in cartilage repair, therefore resulting in the degeneration of articular cartilage. In clinic, conventional treatment for early-stage OA mainly included nonsteroidal anti-inflammatory drugs (NSAIDs), hyaluronic acid, and corticosteroid injections. Nevertheless, these therapies did not reverse the OA process, but just alleviated OA symptoms temporarily. The alternative joint replacement surgery was effective for severe OA, however, limited to its complex revision requirement and life span. In addition, the surgery therapy is not suitable for young patients.

Mesenchymal stem cells (MSCs) are a type of precursor cells with a wide range of sources and can be isolated from bone marrow tissue, adipose tissue, synovium, skeletal muscle, cord blood, and other tissues. Compared with primary cultured chondrocytes, MSC is easier to culture in vitro, and sufficient cells can be obtained within shorter time. In recent years, MSCs derived from bone marrows (BMSCs) were applied to OA treatment both in animal models and clinical practice by promoting cartilage repair and retarding OA progression. MSCs in combination with some materials or factors have also been shown to facilitate the articular cartilage repair for OA treatment.

Turmeric derived from Curcuma longa is commonly used in Indian and some Asian cooking as a spice for curry power. The curcuminoids in turmeric are curcumin, demethoxycurcumin, and bisdemethoxycurcumin, with curcumin being the main active component. Curcumin displayed multiple pharmacological activities including anti-inflammatory, antioxidant, and anticancer, and has been employed in different studies involving several pathologies such as cardiovascular disease, depression, Alzheimer’s disease, epilepsy, Parkinson’s disease, cancer, osteoporosis, rheumatic arthritis, and OA. Curcumin is a natural product medicine displayed nearly no side effects, thus making it a potential alternative to NSAIDs and some other medications with known severe adverse effects. The current study aims to explore the pharmacological action of BMSCs supplemented with curcumin on articular chondrocytes in vitro and the therapeutic potential in vivo.

Materials and Methods

Isolation and Culture of BMSCs

Animal experiments in the current study were approved by the Institutional Ethics Committee of Honghui Hospital, Xi’an Jiaotong University. Male Sprague-Dawley (SD) rats, weighing about 200 g, were purchased from the experimental animal center of Xi’an Jiaotong University. Under sterile conditions, the femurs and tibias of SD rats were carefully separated and washed with phosphate-buffered saline (PBS). Then, bone marrow tissues were collected from the cavities of the femurs and tibias with a 10 ml syringe injected into 6 ml culture medium containing Dulbecco’s modified Eagle’s medium/F12 medium (HyClone, Logan, UT, USA), 1.5 mM l-glutamine (Sigma-Aldrich, St. Louis, MO, USA), 10% fetal bovine serum (Gibco, Melbourne, Australia), 100 U/ml penicillin, and 100 pg/ml streptomycin (HyClone). Cells were maintained in an incubator with 5% CO2, 95% humidity, and 37°C environment. The adherent cells were cultured along with medium exchange every 3 days until the confluence reached 80%. Thereafter, cells were passaged at 1:3 and the passage 3 cells were used for subsequent experiments.

Isolation and Culture of Articular Chondrocytes

Under sterile conditions, the surface layer of the knee articular cartilage was carefully removed, cut into pieces, digested with 0.25% trypsin (HyClone) for 20 min, and 0.2% type II collagenase (Sigma) at 37°C with shaking for 3 h. The 100-μm filter was then used to remove the debris. After centrifugation, the cells were maintained in the same medium as that used in BMSCs culture.

Immunofluorescent and Toluidine Blue Staining

Passage 3 BMSCs or chondrocytes seeded in coverslips were fixed with paraformaldehyde for 20 min. The cells were incubated with primary detection antibodies against primary antibodies (CD44 and CD90, Abcam, Cambridge, UK, 1:1,000; Col2a1, ZSGB-BIO, Beijing, China, 1:400) at 4°C overnight. Subsequently, cells were incubated with anti-rabbit CY3-conjugated secondary antibodies and/or mouse fluorescein isothiocyanate (FITC)-conjugated and/or anti-rabbit CY3-conjugated secondary antibodies (Boster, Beijing, China, 1:200) for 2 h. The cells were then labeled with 4’,6-diamidino-2-phenylindole for 3 min and images were acquired under a fluorescence microscope. For toluidine blue staining, chondrocytes were stained with 1% toluidine blue for 15 min and photographed under an inverted microscope.
Flow Cytometry

Passage 3 BMSCs were digested with 0.25% trypsin, collected, and centrifuged at 1,000 g for 5 min, and the supernatant was discarded. Then the cells were resuspended with 1 x 10^6 cells in 100 µl PBS and incubated with 10 µl CD90 (eBioscience, San Diego, CA, USA) antibody directly conjugated with FITC and 10 µl CD44 (eBioscience) with PE simultaneously for 30 min at room temperature and in dark. Subsequently, the cells were washed two times with PBS and resuspended in 100 µl PBS to perform flow cytometry analysis (BD Biosciences, San Jose, CA, USA).

Cell Counting Kit-8 Assay

Cell viability was evaluated by Cell Counting Kit-8 (CCK-8) assay following the instructions of manufacturer. Briefly, cells were seeded in a 96-well plate at 3 x 10^3 cells/well overnight and then treated with curcumin at different concentrations. After 24 h, 10 µl of CCK-8 solution (Boster, Wuhan, China) was added into each well and the mixture was incubated for 2 h at 37°C with 5% CO₂. Finally, the absorbance was recorded using a Microplate Reader (Thermo Fisher Scientific) at 450 nm.

EdU Assay

Articular chondrocytes were seeded in the lower chamber of 24-well transwell plates (5 x 10^4 cells/well) and cocultured with BMSCs (2 x 10^5 cells/well) seeded in the upper chamber (0.4 µm pore size). After incubation for 24 h at 37°C, chondrocyte proliferation was determined using an EdU assay kit (Solarbio, Beijing, China) according to the manufacturer’s instructions.

Migration Assay

Articular chondrocytes (3 x 10^4 cells/well) were seeded in the upper chamber (8 µm pore size) of 24-well transwell plates and cocultured with BMSCs (2 x 10^5 cells/well) seeded in the lower chamber. After incubation for 24 h at 37°C, the inserts were fixed with 4% paraformaldehyde for 20 min and stained with 0.5% crystal violet solution (Solarbio, Beijing, China) for 15 min. Unmigrated cells on the upper surface of the insert membrane were carefully wiped with a cotton swab.

RNA Extraction and Real-time Quantitative Polymerase Chain Reaction

Articular chondrocytes were seeded in the lower chamber of six-well transwell plates (1 x 10^5 cells/well) and cocultured with BMSCs (2 x 10^5 cells/well) seeded in the upper chamber (0.4 µm pore size). Total RNA was extracted after 24 h and reverse transcribed to first-strand cDNA according to the manufacturer’s instructions (Thermo Fisher Scientific). Expression of Aggrecan, Col2a1, Sox9, and the internal control gene Gapdh was quantified with quantitative polymerase chain reaction using FastStart Universal SYBR Green Master (Rox, CO, USA). The primers used in the study are listed in Table 1.

| Gene name | Sequence (5′–3′) |
|-----------|-----------------|
| Aggrecan  | For: TCCACATCGAAGAGCCATAC; Rev: AGTCGAAGTCGGCAAGG |
| Col2a1    | For: TGAGGAAGCTTGGAGAGACG; Rev: TGAGGAAGCTTGGAGAGACG |
| Sox9      | For: CGAGAACACCGACACTGTC; Rev: TGTCGACGGCAGTCCAG |
| Gapdh     | For: TGAGGAACCAGTTGTCTTCC; Rev: ATGTAAGCCATGAGTCCAC |

PCR: polymerase chain reaction.

Protein Extraction and Western Blotting

Articular chondrocytes were cocultured with allogeneic BMSCs in six-well transwell plates. Total proteins were extracted, quantified, separated, and transferred to polyvinylidene difluoride membranes as described previously. The membranes were incubated with primary detection antibodies against Sox9 (CST, Boston, MA, USA, 1:1,000), Col2a1(Boster, Wuhan, China, 1:200), Aggrecan (Abways, Shanghai, China, 1:400), and Actin (Abcam, 1:1,000); Actin was used as the internal control. Membranes were then incubated with anti-rabbit immunoglobulin G secondary detection antibody (Thermo Fisher Scientific, 1:5000).

Induction of OA Model by Intra-articular Injection of Monoiodoacetic Acid and Treatment

Forty-two male SD rats were used for the in vivo experiment in the current study. Six rats were not subjected to any intervention used as control group. Thirty-six rats were used to induce OA animal model. Briefly, under sterile conditions, the animals were anesthetized with 3% pentobarbital sodium and injected with 2 mg monoiodoacetic Acid (MIA) dissolved in 50 µl DMSO every 3 days, and then the rats were randomly divided into three groups, namely, the OA, BMSC, and BMSC + CCM (curcumin) groups. In our previous research, intra-articular injection of 50 mg/kg/d curcumin showed some treatment effects on OA rats induced by MIA. The rats in BMSC group were intra-articularly injected with 1 x 10^6 BMSCs suspended in 50 µl PBS into right knee for one time and intra-articularly injected with 50 mg/kg/d curcumin dissolved in 50 µm dimethyl sulfoxide (DMSO) every day for 2 weeks. Correspondingly, the rats in BMSC group were intra-articularly injected with 1 x 10^6 BMSCs in 50 µl PBS and intra-articularly injected with 50 µl DMSO; the rats in OA group were injected 50 µl PBS.
and 50 μl DMSO. All the rats were sacrificed under anesthesia condition 4 weeks later.

**Histological Staining and OA Score Analyses**

The femoral condyles were collected from the sacrificed rats, fixed with 4% paraformaldehyde for 48 h, decalcified with 12.5% ethylenediaminetetraacetic acid for 4 weeks, and dehydrated with 30% sucrose solution for 72 h. The articular cartilage was then isolated, frozen, and embedded in OCT compound (Tissue-Tek, Tokyo, Japan). Finally, sections of 7 μm thick were cut in the sagittal plane with a freezing microtome (Leica, Heidelberg, Germany). The frozen sections were fixed again with acetone solution for 10 min, and then stained with hematoxylin and eosin (HE), toluidine blue, and safranin O (Solarbio, Shanghai, China), respectively. The Osteoarthritis Research Society International (OARSI) scoring system was used to determine the extent of cartilage deterioration and the severity of knee OA, with scores ranging from 0 (normal) to 6 (>80% loss of cartilage). The modified Mankin criteria were used to assess cartilage damage, with scores ranging from 0 (normal) to 24 (the most severe OA)28. The evaluations were performed independently by two blinded observers and the scores were evaluated in OA, BMSC, and BMSC + CCM groups.

**Statistical Analysis**

Data were presented as the mean ± standard error of the mean. All experiments were performed at least three independent occasions. One-way analysis of variance was used to determine statistical differences and post hoc analyses were carried out using the least significance difference tests. SPSS18.0 software was used for statistical analysis. P < 0.05 was considered to indicate statistical significance.

**Results**

**Culture and Identification of BMSCs and Articular Chondrocytes**

BMSCs and articular chondrocytes of rats were cultured and the media were changed every 2 to 3 days. The cells were imaged under inverted microscope at different time points. At 3 and 5 days, a small number of BMSCs adhered and the cells showed a spindle-shaped appearance with no distinct morphological differences. With the culture period over 9 days, cells multiplied to form a confluent monolayer, exhibiting fibroblast-like appearance and morphologically homogeneous (Fig. 1A). Immunofluorescent staining of CD44 and CD90, which are characteristic markers for BMSCs, demonstrated positive staining for the cells (Fig. 1B). Flow cytometry analysis of BMSC revealed that the percentage of CD44 and CD90 positive cells was over 95% (Fig. 1C). Articular chondrocytes showed long spindle-shaped appearance and the confluence reached about 70% following 7 days of culture (Fig. 2A). The toluidine blue staining and immunofluorescent staining of Col2a1 for the cells were positive (Fig. 2A, B).

**Curcumin at Low Concentration Showed No Effects on the Proliferation of Articular Chondrocytes**

Curcumin is a natural polyphenol product, and the chemical structure of curcumin was shown in Fig. 3A. CCK-8 assay was used to evaluate the effects of curcumin on the proliferation of articular chondrocytes. Curcumin with concentration more than 20 μM displayed cytotoxicity on articular chondrocytes (Fig. 3B). Cell viability was not significantly influenced by curcumin at low concentration (less than 20 μM) and therefore curcumin with 8 μM was used to perform further experiment (Fig. 3B).

**Curcumin Supplementation Enhanced Proliferation and Migration of Articular Chondrocytes Cocultured with BMSCs**

The effect of BMSCs and curcumin supplementation on articular chondrocytes cocultured with BMSCs was assessed by EdU incorporation assays (Fig. 4A). The percentage of EdU-positive cells was significantly increased in BMSC group compared with controls, suggesting that BMSCs promoted the proliferation of articular chondrocyte (Fig. 4B). In the migration assay, the number of migratory chondrocytes in BMSC group was remarkably increased compared with control group and in BMSC + CCM group was significantly increased compared with control and BMSC group, indicating that BMSCs greatly accelerated chondrocyte migration and curcumin supplementation enhanced this function of BMSC on chondrocytes (Fig. 4C).

**Curcumin Supplementation Increased Anabolic Gene Expression in Articular Chondrocytes Cocultured with BMSCs**

Articular chondrocytes synthesize the components of ECM, including collagens and proteoglycans. The balance between anabolic and catabolic mechanisms maintains ECM homeostasis in articular cartilage, and the imbalance is associated with the destruction of OA cartilage29. Col2a1 and Aggrecan are the main anabolic components in the ECM, and Sox9 is a crucial transcription factor for the gene expression30. Cocultured with BMSCs, the expression of Col2a1, Aggrecan, and Sox9 in articular chondrocytes with or without curcumin was significantly increased compared with controls at mRNA level (Fig. 5A). When curcumin was added to the chondrocytes cocultured with BMSCs, the expression of these genes was remarkably increased.
increased, suggesting that curcumin supplementation enhances anabolic gene expression in articular chondrocytes cocultured with BMSCs (Fig. 5B). Correspondingly, curcumin supplementation enhanced the expression of these genes in chondrocytes cocultured with BMSCs at protein level (Fig. 5C–E).

Curcumin Supplementation Assisted BMSCs to Promote Articular Cartilage Repair and Alleviate OA Progression

MIA was used to induce OA model in SD rats. Four weeks later, HE staining results demonstrated that the articular cartilage layer was thin and the number of articular chondrocytes was reduced in OA rats (Fig. 6A). Further toluidine and safranin O staining indicated that glycosaminoglycan and Aggrecan content was decreased in articular cartilage of OA rats (Fig. 6A). Treated by BMSCs, the damage of articular cartilage was greatly improved and curcumin supplementation further promoted the repair process (Fig. 6A). Accordingly, the OARSI and Mankin scores for OA and treated rats demonstrated that BMSCs could alleviate OA progression and curcumin supplementation further improved the treatment effects (Fig. 6B, C).

Discussion

OA is a chronic musculoskeletal degenerative and ageing related disease. In recent years, MSCs as a regeneration medicine showed promising potential in OA treatment. In the current study, although curcumin alone did not improve cell viability of primary articular chondrocytes, it enhanced proliferation and migration of chondrocytes when...
cocultured with BMSCs. Meanwhile, the expression of anabolic genes in chondrocytes related to ECM synthesis was remarkably increased both at mRNA and protein levels.

In OA rats, curcumin and BMSCs cooperating to greatly promote articular cartilage regeneration and retard OA progression.

OA could be simulated in vitro by stimulating primary articular chondrocytes with IL-1β, which serve important roles in articular cartilage damage. Curcumin demonstrated anti-inflammation potential by inhibiting the IL-1β-induced activation through regulating NF-κB signal pathway in rat or human articular chondrocytes. In OA rats, TLR4 activation was involved in OA mechanism and intraperitoneal injection of curcumin reduced inflammation through blocking TLR4/MyD88/NF-κB signal pathway.

In OA patients, the released proinflammatory cytokine IL-1β could further stimulate the synthesis of more inflammatory cytokines and induce chondocyte apoptosis. These cytokines could further induce matrix degradation by producing catabolic enzymes such as matrix metalloproteinases (MMPs). IL-1β also inhibited the expression of cartilage-specific ECM components including COL2A and cartilage-specific Aggrecans. Curcumin could inhibit IL-1β-induced apoptosis and caspase-3 activation and promote autophagy through activation of ERK1/2 signaling pathways in rat articular chondrocytes. In spontaneous and surgically induced OA mice models, curcumin treatment could enhance autophagy and reduce apoptosis and articular cartilage loss. Meanwhile, the in vitro experiment demonstrated that oral administration of curcumin inhibited apoptosis and promoted autophagy through regulating Akt/mTOR pathway. The pathophysiology of OA...
was also related with mitochondrial function in articular chondrocytes of OA patients, and curcumin could suppress endoplasmic reticulum (ER) stress in chondrocytes induced by tert-Butyl hydroperoxide via promoting SIRT1 expression to inhibit PERK-ELF2α-CHOP axis. In OA rats induced by surgical transection of right anterior cruciate ligament, intraperitoneal injection of curcumin inhibited ER stress and ameliorated cell apoptosis in articular cartilage. Therefore, curcumin exerts anti-inflammatory, antiapoptotic, and antioxidant by regulating specific signal pathways and has chondroprotective effects.

In recent years, increasing evidence showed that most intra-articularly injected MSCs were rarely or not engrafted in the articular cartilage and the therapeutic function of the injected MSCs is mainly attributed to their paracrine effects. MSCs could secrete extracellular vesicles (EV)
containing abundant trophic factors to modulate the injured tissue microenvironment for cartilage regeneration via proliferation, differentiation, and ECM synthesis. Exosomes and microvesicles are the two main categories of EV according to their size and biogenesis. Intra-articular injection of microvesicles and exosomes of BMSCs exerted similar chondroprotective and anti-inflammatory function in vitro and protected mice from developing OA in vivo, suggesting that either exosomes or microvesicles reproduced the main therapeutic effect of BMSCs. The study of Wang et al. confirmed that embryonic MSCs alleviate cartilage destruction and ECM degradation, and exosomes derived from embryonic MSCs also successfully impeded cartilage destruction in OA mice. Li et al. found that exosomes derived from MSCs of various sources regulate specific signaling pathways such as p38/ERK/Akt, TGF-ß1/miR-135b/Sp1, and autophagy-related mTOR, and lead to increased synthesis of Col2 and proteoglycans and decreased production of ADAMTS-5 and MMP-13 in vitro and in vivo. Exosomes could restore the homeostasis of the articular microenvironment and remodel the stability of cartilage for knee OA therapies. In the current study, co-culture chondrocytes with BMSCs in transwell may imply the paracrine effects of BMSCs on chondrocytes.
Although the effects of BMSCs on chondrocyte has been well documented, few studies have reported the effect of curcumin on BMSCs. Buhrmann et al. reported that although curcumin alone did not have chondrogenic effects on MSCs, it inhibits IL-1β-induced activation of NF-κB, caspase-3, and COX2 in MSCs as well as in chondrocytes. Curcumin further promoted chondrogenic differentiation, which was suppressed by the proinflammatory factor when the cells received a chondrogenic stimulus or mixedly cultured with articular primary chondrocytes. They speculated that curcumin treatment might help to establish a microenvironment in which the effects of proinflammatory cytokines are antagonized, thus facilitating chondrogenesis of MSC-like progenitor cells in vivo. Cao et al. further validated that curcumin had no effects on the expression of chondrogenic markers in the process of chondrogenic differentiation in MSCs. Their further exploration demonstrated that curcumin inhibited chondrocyte hypertrophy through Indian hedgehog homolog and Notch signal pathways in MSCs. In our study, we found that curcumin enhanced the effects of BMSCs on primary articular chondrocytes, including cell proliferation and migration, and on the expression of anabolic markers at mRNA and protein levels for chondrogenesis, indicating that curcumin might interact with trophic factors.
factors released from BMSCs, and improve the cultured condition for articular chondrocytes.

The in vivo experiment in OA rats induced by MIA further proved that curcumin supplementation enhanced the therapeutic effects of BMSCs for OA disease. MIA has an inhibitory effect on the activity of glyceraldehydes-3 phosphate dehydrogenase in chondrocytes resulting in disruption of glycolysis, reduces quantity and synthesis of proteoglycans, and eventually leads to cell death. Intra-articular injection of MIA caused histological and biochemical changes in articular cartilage of the knee joint resembling human knee OA symptoms. Combining intra-articular injection of BMSCs and localized application of curcumin, we treated the MIA induced rats equivalent to human OA at early stage. Localized treatment of curcumin in OA was minimally invasive and had effect on pain relief. The results in current study demonstrated that BMSCs promoted cartilage repair and retarded OA progression at early stage, which was greatly enhanced by curcumin supplementation. This enhanced effect may correlate with the interaction between curcumin and trophic factors secreted from BMSCs, which could regulate the microenvironment of the joint cavity for articular cartilage regeneration and thereby promoting the therapeutic effect for OA treatment. Further studies regarding the interaction and molecular mechanisms are warranted. In addition, BMSCs primed with proinflammatory cytokines could improve their homing and immunomodulatory functions. Whether BMSCs primed with curcumin could improve their function and promote their therapeutic effects for OA treatment is very interesting and deserves further studying.

Conclusion

In conclusion, the balance between anabolic and catabolic of ECM is vital for articular cartilage. BMSCs provide great promising potential for repairing damaged cartilage in OA disease. In the current study, curcumin enhanced the BMSC function for the proliferation and migration of articular chondrocytes, and anabolic gene expression of ECM in articular chondrocytes in vitro, and the regeneration of articular cartilage in vivo. These results indicated potential clinical application of curcumin cooperation with BMSCs in cartilage repair for OA treatment.

Ethical Approval

This study was approved by the Medical Ethics Committee of Honghui Hospital, Xi’an Jiaotong University, China.

Statement of Human and Animal Rights

All procedures in this study were conducted in accordance with the Institutional Animal Care guidelines of Xi’an Jiaotong University, China, and approved by the Administration Committee of Experimental Animals, Shaanxi Province, China.

Statement of Informed Consent

There are no human subjects in this article and informed consent is not applicable.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The current study was supported by the Natural Science Foundation of Shaanxi Province (No. 2018JM7039, No. 2018JM7081) and the National Natural Science Foundation of China (No. 81601913).

ORCID iD

Rui Zhang https://orcid.org/0000-0002-8664-6915

References

1. Hunter DJ, Schofield D, Callander E. The individual and socioeconomic impact of osteoarthritis. Nat Rev Rheumatol. 2014;10(7):437–441.
2. Prieto-Alhambra D, Judge A, Javaid MK, Cooper C, Diez-Perez A, Arden NK. Incidence and risk factors for clinically diagnosed knee, hip and hand osteoarthritis: influences of age, gender and osteoarthritis affecting other joints. Ann Rheum Dis. 2014;73(9):1659–1664.
3. Hunter DJ, Bijera-Zeinstra S. Osteoarthritis. Lancet. 2019;393(10182):1745–1759.
4. Nelson AE. Osteoarthritis year in review 2017: clinical. Osteoarthritis Cartilage. 2018;26(3):319–325.
5. Loeser RF, Goldring SR, Scanzello CR, Goldring MB. Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum. 2012;64(6):1697–1707.
6. Archer CW, Francis-West P. The chondrocyte. Int J Biochem Cell Biol. 2003;35(4):401–404.
7. Fosang AJ, Beier F. Emerging Frontiers in cartilage and chondrocyte biology. Best Pract Res Clin Rheumatol. 2011;25(6):751–766.
8. Lee AS, Ellman MB, Yan D, Kroin JS, Cole BJ, van Wijnen AJ, Im HJ. A current review of molecular mechanisms regarding osteoarthritis and pain. Gene. 2013;527(2):440–447.
9. Sarzi-Puttini P, Cimmino MA, Scarpa R, Caporali R, Parazzini F, Zaninelli A, Atzeni F, Canesi B. Osteoarthritis: an overview of the disease and its treatment strategies. Semin Arthritis Rheum. 2005;35(1 suppl 1):1–10.
10. Zhang R, Ma J, Han J, Zhang W, Ma J. Mesenchymal stem cell related therapies for cartilage lesions and osteoarthritis. Am J Transl Res. 2019;11(10):6275–6289.
11. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411):143–147.
12. Zhang K, Zhang Y, Yan S, Gong L, Wang J, Chen X, Cui L, Yin J. Repair of an articular cartilage defect using adipose-derived stem cells loaded on a polyelectrolyte complex
scaffold based on poly(l-glutamic acid) and chitosan. Acta Biomater. 2013;9(7):7276–7288.

13. Xia Q, Zhu S, Wu Y, Wang J, Cai Y, Chen P, Li J, Heng BC, Ouyang HW, Lu P. Intra-articular transplantation of atstrin-transduced mesenchymal stem cells ameliorates osteoarthritis development. Stem Cells Transl Med. 2015;4(5):523–531.

14. Seo EJ, Efferth T, Panossian A. Curcumin downregulates expression of opioid-related nociceptin receptor gene (OPRL1) in isolated neuroglia cells. Phytomedicine. 2018;50:285–299.

15. Yang M, Akbar U, Mohan C. Curcumin in autoimmune and rheumatic diseases. Nutrients. 2019;11(5):1004.

16. Qin S, Huang L, Gong J, Shen S, Huang J, Ren H, Hu H. Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: a meta-analysis of randomized controlled trials. Nutr J. 2017;16(1):68.

17. Naqvi F, Saleem S, Naqvi F, Butal Z, Sadir S, Tabassum S, Ahmed S, Liaquat L, Haider S. Curcumin lessens unpredictable chronic mild stress-induced depression and memory deficits by modulating oxidative stress and cholinergic activity. Pak J Pharm Sci. 2019;32(Suppl 4):1893–1900.

18. Reddy PH, Manczak M, Yin X, Grady MC, Mitchell A, Tonk S, Kuruva CS, Bhatti JS, Kendrally R, Vijayan M, Kumar S, et al. Protective effects of Indian spice curcumin against amyloid-beta in Alzheimer’s disease. J Alzheimers Dis. 2018;61(3):843–866.

19. Adami R, Bottai D. Curcumin and neurological diseases. Nutr Neurosci. 2020;22(1):1–21.

20. Chen Z, Xue J, Shen T, Mu S, Fu Q. Curcumin alleviates glucocorticoid-induced osteoporosis through the regulation of the Wnt signaling pathway. Int J Mol Med. 2016;37(2):329–338.

21. Zhang Z, Leong DJ, Xu L, He Z, Wang A, Navati M, Kim SJ, Hirsh DM, Hardin JA, Cobelli NJ, Friedman JM, et al. Curcumin slows osteoarthritis progression and relieves osteoarthritis-associated pain symptoms in a post-traumatic osteoarthritis mouse model. Arthritis Res Ther. 2016;18(1):128.

22. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune, and neoplastic diseases. Int J Biochem Cell Biol. 2009;41(1):40–59.

23. Hsu CH, Cheng AL. Clinical studies with curcumin. Adv Exp Med Biol. 2007;595:471–480.

24. Srivastava S, Saksena AK, Khattari S, Kumar S, Dagur RS. Curcuma longa extract reduces inflammatory and oxidative stress biomarkers in osteoarthritis of knee: a four-month, double-blind, randomized, placebo-controlled trial. Inflammopharmacology. 2016;24(6):377–388.

25. Sterzi S, Giordani L, Morrone M, Lena E, Magrone G, Scarpini C, Milighetti S, Pellicciani L, Bravi M, Panni I, Ljoka C, et al. The efficacy and safety of a combination of glucosamine hydrochloride, chondroitin sulfate and bio-curcumin with exercise in the treatment of knee osteoarthritis: a randomized, double-blind, placebo-controlled study. Eur J Phys Rehabil Med. 2016;52(3):321–330.

26. Wu S, Zhang R, Nie F, Wang X, Jiang C, Liu M, Valenzuela RK, Liu W, Shi Y, Ma J. MicroRNA-137 inhibits EFN2B expression affected by a genetic variant and is expressed aberrantly in peripheral blood of schizophrenia patients. EBioMedicine. 2016;12:133–142.

27. Zhou Z, Zhou J, Xiao K, Meng F, Zhu T, Rui Z. Therapeutic effects of curcumin on rats with knee osteoarthritis in duced by monoiodoacetic acid. J XJTU (MS). 2020;41(2):299–302.

28. Huesca C, Ortiz AC, Dunning L, McGavin L, Bennett L, McIntosh K, Crilly A, Krusowska-Stolarska M, Plevin R, van ‘t Hof RJ, Rowan AD, et al. Proteinase-activated receptor 2 modulates OA-related pain, cartilage and bone pathology. Ann Rheum Dis. 2016;75(11):1989–1997.

29. Alcaraz MJ, Megias J, Garcia-Armandis I, Clerigues V, Guillen M. New molecular targets for the treatment of osteoarthritis. Biochem Pharmacol. 2010;80(1):13–21.

30. Mackie EJ, Tatarczuch L, Mirams M. The skeleton: a multifunctional complex organ: the growth plate chondrocyte and endochondral ossification. J Endocrinol. 2011;211(2):109–121.

31. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest. 2008;118(11):3537–3545.

32. Wang J, Ma J, Gu JH, Wang FY, Shang XS, Tao HR, Wang X. Regulation of type II collagen, matrix metalloproteinase-13 and cell proliferation by interleukin-1beta is mediated by curcumin via inhibition of NF-kappaB signaling in rat chondrocytes. Mol Med Rep. 2017;16(2):1837–1845.

33. Csaki C, Mobasher A, Shakibaei M. Synergistic chondroprotective effects of curcumin and resveratrol in human articular chondrocytes: inhibition of IL-1beta-induced NF-kappaB-mediated inflammation and apoptosis. Arthritis Res Ther. 2009;11(6):R165.

34. Kim L, Kim JY. Chondroprotective effect of curcumin and lecitin complex in human chondrocytes stimulated by IL-1beta via an anti-inflammatory mechanism. Food Sci Biotechnol. 2019;28(2):547–553.

35. Yan D, He B, Guo J, Li S, Wang J. Involvement of TLR4 in the protective effect of intra-articular administration of curcumin on rat experimental osteoarthritis. Acta Cir Bras. 2019;34(6):e201900604.

36. Zhang Y, Zeng Y. Curcumin reduces inflammation in knee osteoarthritis rats through blocking TLR4/MyD88/NF-kappaB signal pathway. Drug Res Dev. 2019;80(3):353–359.

37. Blanco FJ, Gutierrez R, Moreno J, de Toro FJ, Galdo F. Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J Rheumatol. 1999;26(6):1366–1373.

38. Wojdasiewicz P, Poniatowski LA, Szukiewicz D. The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis. Mediators Inflamm. 2014;2014:561459.

39. Murakami S, Lefebvre V, de Crombrugghe B. Potent inhibition of the master chondrogenic factor sox9 gene by interleukin-1 and tumor necrosis factor-alpha. J Biol Chem. 2000;275(5):3687–3692.
40. Li X, Feng K, Li J, Yu D, Fan Q, Tang T, Yao X, Wang X. Curcumin inhibits apoptosis of chondrocytes through activation ERK1/2 signaling pathways induced autophagy. Nutrients. 2017;9(4):414.

41. Zhang G, Cao J, Yang E, Liang B, Ding J, Liang J, Xu J. Curcumin improves age-related and surgically induced osteoarthritis by promoting autophagy in mice. Biosci Rep. 2018;38(4):BSR20171691.

42. Liu H, Li Z, Cao Y, Cui Y, Yang X, Meng Z, Wang R. Effect of chondrocyte mitochondrial dysfunction on cartilage degeneration: a possible pathway for osteoarthritis pathology at the subcellular level. Mol Med Rep. 2019;20(4):3308–3316.

43. Feng K, Ge Y, Chen Z, Li X, Liu Z, Li X, Li H, Tang T, Yang F, Wang X. Curcumin inhibits the PERK-eIF2alpha-CHOP Pathway through promoting SIRT1 expression in oxidative stress-induced rat chondrocytes and ameliorates osteoarthritis progression in a rat model. Oxid Med Cell Longev. 2019;2019:8574386.

44. Chiang ER, Ma HL, Wang JP, Liu CL, Chen TH, Hung SC. Allogeneic mesenchymal stem cells in combination with hyaluronic acid for the treatment of osteoarthritis in rabbits. PLoS One. 2016;11(2):e0149835.

45. Kuroda K, Kabata T, Hayashi K, Maeda T, Kajino Y, Iwai S, Fujita K, Hasegawa K, Inoue D, Sugimoto N, Tsuchiya H. The paracrine effect of adipose-derived stem cells inhibits osteoarthritis progression. BMC Musculoskelet Disord. 2015;16:236.

46. Toh WS, Foldager CB, Pei M, Hui JH. Advances in mesenchymal stem cell-based strategies for cartilage repair and regeneration. Stem Cell Rev Rep. 2014;10(5):686–696.

47. van Niel G, D’Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018;19(4):213–228.

48. Cosenza S, Ruiz M, Toupet K, Jorgensen C, Noel D. Mesenchymal stem cells derived exosomes and microparticles protect cartilage and bone from degradation in osteoarthritis. Sci Rep. 2017;7(1):16214.

49. Wang Y, Yu D, Liu Z, Zhou F, Dai J, Wu B, Zhou J, Heng BC, Zou XH, Ouyang H, Liu H. Exosomes from embryonic mesenchymal stem cells alleviate osteoarthritis through balancing synthesis and degradation of cartilage extracellular matrix. Stem Cell Res Ther. 2017;8(1):189.

50. Li Z, Li M, Xu P, Ma J, Zhang R. Compositional Variation and functional mechanism of exosomes in the articular microenvironment in knee osteoarthritis. Cell Transplant. 2020;29:963689720968495.

51. Buhrmann C, Mobasher A, Matis U, Shakibaee M. Curcumin mediated suppression of nuclear factor-kappaB promotes chondrogenic differentiation of mesenchymal stem cells in a high-density co-culture microenvironment. Arthritis Res Ther. 2010;12(4):R127.

52. Cao Z, Dong S. Curcumin inhibits chondrocyte hypertrophy of mesenchymal stem cells through ihh and notch signaling pathways. Chem Pharm Bull (Tokyo). 2017;65(8):762–767.

53. Beyreuther B, Callizot N, Stohr T. Antinociceptive efficacy of losartanamide in the monosodium iodoacetate rat model for osteoarthritis pain. Arthritis Res Ther. 2007;9(1):R14.

54. Naveen SV, Ahmad RE, Hui WJ, Suhaeb AM, Murali MR, Shankumgam R, Kamarul T. Histology, glycosaminoglycan level and cartilage stiffness in monoiidoacetate-induced osteoarthritis: comparative analysis with anterior cruciate ligament transection in rat model and human osteoarthritis. Int J Med Sci. 2014;11(1):97–105.

55. Udo M, Muneta T, Tsuji K, Ozeki N, Nakagawa Y, Ohara T, Saito R, Yanagisawa K, Koga H, Sekiya I. Monoiidoacetate cistic acid induces arthritis and synovitis in rats in a dose- and time-dependent manner: proposed model-specific scoring systems. Osteoarthritis Cartilage. 2016;24(7):1284–1291.

56. Dai L, Zhang X, Hu X, Liu Q, Man Z, Huang H, Meng Q, Zhou C, Ao Y. Silencing of miR-101 prevents cartilage degradation by regulating extracellular matrix-related genes in a rat model of osteoarthritis. Mol Ther. 2015;23(8):1331–1340.

57. Ratanavaraporn J, Soontornvipart K, Shuangshoti S, Shuangshoti S, Damrongsakkul S. Localized delivery of curcumin from injectable gelatin/Thai silk fibroin microspheres for anti-inflammatory treatment of osteoarthritis in a rat model. Inflammopharmacology. 2017;25(2):211–221.

58. Zachar L, Bacenkova D, Rosocha J. Activation, homing, and role of the mesenchymal stem cells in the inflammatory environment. J Inflam Res. 2016;9:231–240.